Can you take Haemophilus b conjugate (hboc) vaccine with Vivimusta?
1 drug interaction and 5 additional warnings found for the following 2 drugs:
- haemophilus b conjugate (hboc) vaccine
- Vivimusta (bendamustine)
Drug interactions
Moderate drug interactions
Moderate:
haemophilus b conjugate (HbOC) vaccine bendamustine
Applies to: haemophilus b conjugate (hboc) vaccine and Vivimusta (bendamustine)
If you are currently being treated or have recently been treated with bendamustine, you should let your doctor know before receiving haemophilus b conjugate (HbOC) vaccine. Depending on the dose and length of time you have been on bendamustine, you may have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of bendamustine therapy. If you have recently been vaccinated with haemophilus b conjugate (HbOC) vaccine, your doctor may choose to postpone treatment with bendamustine for a couple of weeks or more. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
5 potential interactions Applies to: 4 conditions, including Liver Disease, Infection, Renal Dysfunction, and Bone Marrow Depression/Low Blood Counts.
Bone Marrow Depression/Low Blood Counts
Moderate:
Vivimusta
The bendamustine in Vivimusta has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.
Adult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death. Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections. Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.
Moderate:
Vivimusta
The bendamustine in Vivimusta has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.
Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.
Infection
Moderate:
Vivimusta
The bendamustine in Vivimusta has a moderate potential interaction with Infection.
Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.
Liver Disease
Major:
Vivimusta
The bendamustine in Vivimusta has a major potential interaction with Liver Disease.
Bendamustine injection should be used with caution in patients with hepatic impairment. Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.
Renal Dysfunction
Major:
Vivimusta
The bendamustine in Vivimusta has a major potential interaction with Renal Dysfunction.
Bendamustine injection should be used with caution in patients with mild or moderate renal impairment. Bendamustine injection should not be used in patients with CrCL < 40 mL/min.
Report options
More resources
haemophilus b conjugate (hboc) vaccine
A total of 340 drugs are known to interact with haemophilus b conjugate (hboc) vaccine.
- Haemophilus b conjugate (hboc) vaccine is in the drug class bacterial vaccines.
Vivimusta
A total of 313 drugs are known to interact with Vivimusta.
- Vivimusta is in the drug class alkylating agents.
- Vivimusta is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.